Inclacumab
Inclacumab (pronounced in-klak-yoo-mab) is a type of monoclonal antibody used in the field of medicine and pharmacology. It is designed to bind to specific cells or proteins and stimulate the immune system to attack those cells.
Etymology
The name "Inclacumab" follows the INN naming convention for monoclonal antibodies, with the "-mab" suffix indicating it is a monoclonal antibody. The prefix "Incla-" does not have a specific meaning in the INN naming convention.
Usage
Inclacumab is currently being studied for its potential use in the treatment of various cardiovascular diseases. It works by targeting and inhibiting the P-selectin protein, which plays a key role in the inflammation and damage that can occur in the blood vessels of people with these diseases.
Related Terms
- Monoclonal Antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- P-selectin: A protein that plays a key role in the inflammation and damage that can occur in the blood vessels of people with cardiovascular diseases.
- Cardiovascular Diseases: A class of diseases that involve the heart or blood vessels.
See Also
External links
- Medical encyclopedia article on Inclacumab
- Wikipedia's article - Inclacumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski